🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 98386D307 (prev. 98386D109 )
- Market Cap
- Micro Cap · $12 Million
- ADR Ratio
- 1:100
- Previous Symbol
- XTLBY (changed 7/15/2013)
Business: XTL Biopharmaceuticals Ltd. is a biopharmaceutical company focused on the acquisition, development, and commercialization of proprietary products and late-stage pharmaceutical product candidates for the treatment of unmet medical needs.
Notes: January 25, 2017 -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) , a clinical-stage biopharmaceutical company, today announced the Company has authorized The Bank of New York Mellon, as depository, to effect on February 10, 2017 a change in the ratio from one (1) Depositary Share (DS) representing twenty (20) ordinary shares to a new ratio of one (1) DS representing one hundred (100) ordinary shares. February 10, 2017, DS holders of XTL will be required on a mandatory basis to surrender their old DSs to BNY Mellon for cancellation at the rate of five (5) OLD DSs (CUSIP# 98386D208) for one (1) NEW DS (CUSIP# 98386D307). __________ 10/3/2012 1-10 R/S concurrent with a ratio change. The ADR Ratio will change from one (1) ADS: two (2) Ordinary Share to a new ratio of one (1) ADS: twenty (20) Ordinary Share]. Holders of XTL BioPharmaceuticals will be required on a mandatory basis to surrender their Old ADSs to BNY Mellon in exchange for the New ADSs. ONly whole DRs will be distributed.
Company Contact
- CEO
- Josh Levine
- CFO
- Ronen Twito
- Investor Relations
- Stephanie Carrington, ICR Inc. · 646-277-1282 · Stephanie.Carrington@icrinc.com